Alnylam, gene-silencing and biotech in 2020: the pharmaphorum podcastAlnylam’s Brendan Martin joined the pharmaphorum podcast for episode 23 to talk about his company’s work in gene-silencing Share XAlnylam, gene-silencing and biotech in 2020: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/alnylam-gene-silencing-biotech-2020/
Alnylam’s Anant Murthy on making it as a US biotech in EuropeAlnylam’s European head of market access and GM of mid-size markets, Anant Murthy, shares his perspective on how Share XAlnylam’s Anant Murthy on making it as a US biotech in Europehttps://pharmaphorum.com/r-d/views-analysis-r-d/alnylam-anant-murthy-on-making-it-as-a-us-biotech-in-europe/
UK patients get early access to Alnylam’s ultra-rare disease drug lumasiranThe UK’s regulator has granted early access to Alnylam’s ultra-rare disease drug lumasiran, allowing patients with primary hyperoxaluria Share XUK patients get early access to Alnylam’s ultra-rare disease drug lumasiranhttps://pharmaphorum.com/news/uk-patients-get-early-access-to-alnylams-ultra-rare-disease-drug-lumasiran/
Alnylam’s shares dip as analyst backs rival after rare disease data revealAlnylam has revealed the data that forms the basis of its filings for its latest potential rare disease Share XAlnylam’s shares dip as analyst backs rival after rare disease data revealhttps://pharmaphorum.com/news/alnylams-shares-dip-as-analyst-backs-rival-after-rare-disease-data-reveal/
Alnylam files its third RNAi drug lumasiran in rare kidney diseaseGene-silencing specialist Alnylam has completed filings in the US and EU for lumasiran, which aced a phase 3 Share XAlnylam files its third RNAi drug lumasiran in rare kidney diseasehttps://pharmaphorum.com/news/alnylam-files-its-third-rnai-drug-lumasiran-in-rare-kidney-disease/
AZ adds gene silencing tech to pipeline with Silence Therapeutics dealAstraZeneca has announced a collaboration with UK biotech Silence Therapeutics to develop gene silencing drugs for cardiovascular, renal, Share XAZ adds gene silencing tech to pipeline with Silence Therapeutics dealhttps://pharmaphorum.com/news/az-adds-gene-silencing-tech-to-pipeline-with-silence-therapeutics-deal/
Alnylam gets CHMP backing for second gene-silencing drug GivlaariAlnylam could be weeks away from getting its second RNA interference drug approved in Europe, after a CHMP Share XAlnylam gets CHMP backing for second gene-silencing drug Givlaarihttps://pharmaphorum.com/news/alnylam-gets-chmp-backing-for-second-gene-silencing-drug-givlaari/
Alnylam to file rare kidney disease drug after trial winAfter years where RNA interference research was in the doldrums, Alnylam is on a roll and is preparing Share XAlnylam to file rare kidney disease drug after trial winhttps://pharmaphorum.com/news/alnylam-to-file-rare-kidney-disease-drug-after-phase-3-win/
FDA approves Alnylam’s second RNAi drug – with $442K annual price tagAlnylam has had a second RNA interference (RNAi) drug approved by the FDA, to treat the ultra-rare disease Share XFDA approves Alnylam’s second RNAi drug – with $442K annual price taghttps://pharmaphorum.com/news/fda-approved-alnylams-second-rnai-drug/
